preoperative combined chemothrapy with docetaxel, cisplatin and S-1 in local advanced gastric cancer; multicentric phase II study

preoperative combined chemothrapy with docetaxel, cisplatin and S-1 in local advanced gastric cancer; multicentric phase II study - preoperative DCS therapy in local advanced gastric cancer

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000002081

Enrollment

Registered

2009-07-01

Start date

2009-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

local advanced gastric cancer (excluding T3-4, bulky N2 &amp

Interventions

2 courses of DCS therapy followed by gastrectomy. docetaxel 35mg/m2/ D1, 8/ q4w cisplatin 35mg/m2/ D1, 8/ q4w S-1 80mg/m2/ D1-14/ q4w

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) histologically confirmed gastric adenocarcinoma 2) local advanced gastric cancer (T3-4, absence of peritoneal metastases confirmed by laparoscopy) 3) esophageal invasion < 3cm 4) age of 20-75 5) PS 0-1 (ECOG) 6) no prior treatment 7) no obvious bleeding from primary tumor 8) enable to ingestion 9) adequate organ function 10) written informed consent

Exclusion criteria

Exclusion criteria: 1) obvious infection 2) severe complication 3) active other malignancies 4) distant metastases 5) motor palalysis or peripheral neuropathy 6) drug hypersensitivity 7) mental disorder 8) possibility of pregnancy 9) judged as unsuitable by the doctor in charge

Design outcomes

Primary

Measure	Time frame
pathological response	—

Countries

Japan

Contacts

Public ContactSachio Fushida

Kanazawa University Hospital Gastroenterological Surgery

fushida@staff.kanazawa-u.ac.jp076-265-2362

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026